探索阿尔茨海默氏症频谱和风险因素中的形态和微观结构特征
Aurélie Bussy1, Raihaan Patel2, Olivier Parent1
1Computational Brain Anatomy (CoBrA) Laboratory, Cerebral Imaging Centre, Douglas Research Centre, 6875 Bd LaSalle CIC Building, Verdun, QC H4H 1R3, Canada; Douglas Mental Health University Institute, 6875 Bd LaSalle, Montreal, QC H4H 1R3, Canada; Integrated Program in Neuroscience, McGill University, Room 302, Irving Ludmer Building, 1033 Pine Ave. W., Montreal, QC H3A 1A1, Canada; Department of Neurology and Neurosurgery, McGill University, 3801 Rue University, Montreal, QC H3A 2B4, Canada.
Neurobiology of aging
|February 17, 2025
概括
早期阿尔茨海默氏症 (AD) 涉及神经系统变化,如髓损失. 定量MRI (qMRI) 显示这些变化与生活方式因素和遗传风险有关,甚至在认知能力下降之前.
科学领域:
- 神经成像是一种神经成像.
- 神经病理学神经病理学
- 老年学是一门学科.
背景情况:
- 早期阿尔茨海默氏症 (AD) 病理生理学涉及神经变化,包括髓退化和与炎症相关的铁积累.
- 确定可靠的生物标志物用于早期AD检测对于及时干预至关重要.
- 多模式神经成像方法可以捕捉复杂的病理变化.
研究的目的:
- 确定与MRI衍生的缩和定量MRI (qMRI) 测量AD频谱中个体中的髓和铁的多模成像特征.
- 研究这些神经成像标记物与认知状态,生活方式因素和遗传倾向之间的关系.
- 评估qMRI指标在检测AD早期病理变化的有用性.
主要方法:
- 在AD频谱中招募了158名参与者:认知不受损,家族AD风险,轻度认知障碍 (MCI) 和AD痴呆症.
- 使用MRI衍生的缩测量和定量MRI (qMRI) 来评估髓和铁含量.
- 分析了神经成像发现,生活方式因素 (吸烟,高血压,高胆固醇,焦虑),年龄,AD进展和APOE-ɛ4载体状态之间的关联.
主要成果:
- 鉴定出一种独特的大脑模式,其特征是皮层厚度下降 (表明神经元损失) 和由于髓减少而导致海马体完整性受损.
- 这种模式与可修改的生活方式因素显著相关,包括吸烟,高血压,高胆固醇和焦虑.
- 还发现了与年龄的增长,阿尔茨海默病的进展和APOE-ɛ4载体状况的关联.
结论:
- 定量MRI (qMRI) 度量作为阿尔茨海默病早期神经变化的敏感,非侵入性指标.
- 这些qMRI标志物与遗传风险 (APOE-ɛ4) 和可修改的生活方式因素有关,即使在临床前阶段.
- qMRI为早期发现和监测AD病理生理学提供了一个有前途的工具,强调了解决风险因素的重要性.
相关概念视频
01:26Alzheimer's Disease: Overview
429
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
429
01:30Dementia
91
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
91
01:22Alzheimer's Disease: Treatment
150
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
150
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K